26 results about "Antidiabetic agents" patented technology

The present invention relates to an anti-diabetic effect of a Cucumis melo leaf extract, particularly an alcohol extract of Cucumis melo leaves. The Cucumis melo leaf extract of the present invention can provide an anti-diabetic effect through a blood glucose-lowering effect. In addition, the Cucumis melo leaf extract of the present invention has a high yield of about 21%, and thus can be high feasibility as an excellent anti-diabetic material.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.

The application discloses a coumarin tyramine glycoside compound and application thereof in preparation of PTP1B inhibitors and anti-diabetic drugs, and a structural formula of the compound is shown in the following formula: wherein R represents a fatty (aromatic) acyl or a monosaccharide substituent, and R' represents a hydrogen atom or an acetyl group; the compound is prepared by taking 4-methoxycoumarin tyramine 4'-acetyl-O-L-rhamnose as a starting material, introducing a fatty (aromatic) acyl or a monosaccharide substituent into a 2-position hydroxyl and a 3-position hydroxyl of L-rhamnose at the same time, and then removing a protecting group of a sugar group. Pharmacological activity tests show that the compound has good inhibitory activity on protein tyrosine phosphatase 1B, and it is indicated that the coumarin tyramine glycoside compound can be researched and utilized as a new type of PTP1B inhibitor and anti-diabetic drug.

The present invention discloses an oleanane-type triazole glycoside compound and its application in the preparation of PTP1B inhibitors and anti-diabetic drugs. The structural formula of the compound is: wherein R represents a saccharide group, which is oleanolic acid C 28 The oleanane-type triazole glycoside is prepared by converting the 3-hydroxyl group of methyl n-aminohexanoate into a 4-pentynyl ester as the starting material, followed by a click reaction with an azidosugar compound to introduce different sugar units. Pharmacological activity tests have shown that the oleanane-type triazole glycoside has excellent inhibitory activity against protein tyrosine phosphatase 1B and can be studied and utilized as a novel PTP1B inhibitor and antidiabetic drug.

The invention discloses a xanthone compound as well as a preparation method and application thereof, the xanthone compound is obtained by taking stems and leaves of dry luteaceae Piper plant Piper as a raw material through extract extraction, organic solvent extraction, silica gel column chromatography and high-pressure liquid chromatography separation, and the molecular formula of the xanthone compound is C28H32O8 or C23H24O5. The xanthone compound can be used for preparing an alpha-glucosidase inhibitor. According to an alpha-glucosidase inhibitory activity experiment, acarbose is selected as a positive control, the IC50 values of the two xanthone compounds to alpha-glucosidase are 23.12 [mu] mol / L and 3.6 [mu] mol / L respectively, and both the xanthone compounds have good alpha-glucosidase inhibitory activity. The compound disclosed by the invention is simple in structure and good in activity, can be used as a pilot compound of an anti-diabetic drug, and has a good application prospect.

A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.

The present invention relates to a use of a composition comprising a zinc salt; and cyclohistidine-proline as an effective ingredient for preventing, ameliorating or treating diabetic nephropathy, and more particularly, to provide a composition comprising a zinc salt; and cyclohistidine-proline as an effective ingredient and a method for preventing, ameliorating or treating diabetic nephropathy using the same, wherein the composition exhibits a preventive, ameliorative or therapeutic effect on diabetic nephropathy through an effect of reducing albuminuria, reducing an albumin / creatinine ratio or increasing glomerular filtration rate when the composition is administered alone or in combination with an antihypertensive agent and / or an antidiabetic agent.

The invention belongs to the technical field of medicines, and discloses a diterpenoid glycoside compound as well as a preparation method and application thereof. According to the invention, the diterpenoid glycoside compound with a novel structure is obtained by taking the chrysosplenium nigrum seeds as a separation target and comprehensively applying various separation technologies and means. In-vitro experiments prove that the diterpenoid glycoside compound provided by the invention has remarkable alpha-glucosidase inhibitory activity, can be used as an active ingredient of an anti-diabetic drug, and has wide application.

Disclosed herein are compositions and methods for transdermal formulations of antidiabetic agents. An example transdermal formulation contains a SGLT2 inhibitor, and is used for the treatment of Type 2 diabetes.

An object of the present invention is to find a novel extract derived from a natural product having a dipeptidyl peptidase-IV inhibitory activity, and to provide a dipeptidyl peptidase-IV inhibitor, an agent for suppressing an increase in blood glucose level, and an antidiabetic agent.SOLUTION: The black ginger extract and the Cullen corylifolium extract have a dipeptidylpeptidase-IV inhibitory activity, and can be used as dipeptidylpeptidase-IV inhibitors, and hypoglycemic agents and antidiabetic agents containing the same.SELECTED DRAWING: None

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The invention provides a fluoromethylated compound of a natural phenolic compound. A preparation method of the fluoromethylated compound of the natural phenolic compound comprises the following step: by taking a phenolic natural product and fluoromethyl p-toluenesulfonate as raw materials, potassium carbonate as alkali and acetonitrile as a solvent, carrying out reflux to prepare the fluoromethylated compound. The reaction product is single and easy to separate, the reaction condition is mild, and the functional group tolerance is good. The product prepared by the invention is applied to anti-diabetic medicines, and a remarkable effect is achieved.

This invention is about the description of the formula in the form of the amount / content of Amino Acids from Swamp Gourami (Trichogaster Trichopterus) from South Kalimantan for the Treatment of Diabetes Mellitus obtained from the latest fish meal processing. It was found that there are 18 types of amino acids with varying levels in swamp gourami meal. Amino acids in swamp gourami meal can support the use of natural ingredients as active ingredients in the treatment of diabetes mellitus so that it can optimize the biodiversity of South Kalimantan waters, especially swamp fish as a source of bioactives that support the development of innovative health products. So that in the future it can develop a formula or pharmaceutical preparation from gourami amino acids that can be applied in the form of capsules, tablets or other innovative preparations for antidiabetic therapy. It is known that the active compound that can have potential as an antidiabetic is a protein compound where the complex protein consists of amino acids.

The invention belongs to the technical field of medicines, and discloses a glucoside acid derivative as well as a preparation method and application thereof. According to the method disclosed by the invention, a plurality of glycoside acid derivatives with novel structures are obtained by comprehensively applying a plurality of separation technologies and means by taking chrysosplenium nigrum seeds as a separation target. In-vitro experiments prove that the glycoside acid derivative provided by the invention has remarkable alpha-glucosidase or PTP1B inhibitory activity, can be used as an active ingredient of an anti-diabetic drug, and has wide application.

The present invention relates to the use of a pharmaceutical carrier in the preparation of an antidiabetic pharmaceutical composition. In particular, the present invention relates to the use of a pharmaceutical carrier in the preparation of an antidiabetic pharmaceutical composition, wherein the pharmaceutical carrier consists of well-mixed sesame oil and beeswax, and the antidiabetic pharmaceutical composition consists of oryzanol and berberine hydrochloride as active ingredients, wherein oryzanol is present in an amount of 1-5% by weight, berberine hydrochloride is present in an amount of 5-50% by weight, beeswax is present in an amount of 1-20% by weight, and sesame oil is present in an amount of 40-85% by weight, based on the total weight of the pharmaceutical composition.The present invention further relates to an antidiabetic pharmaceutical composition as above, which is subjected to compression, washing, drying and screening, and filling into a vial to obtain a soft capsule dosage form product. The product has advantages such as stable control of blood glucose, lowering of blood glucose level and blood lipids, protection of liver function, and reduction of gastrointestinal irritation.

Provided herein are insulin receptor (INSRF) agonist compounds of Formula I-IV or compositions containing the same, the use of these compounds or compositions in the treatment of diabetes. These compounds and compositions can bind to allosteric sites on INSR and cooperate with insulin to activate INSR and downstream signaling pathways by phosphorylating the INSR protein.

The invention relates to methods and pharmaceutical compositions effective for treating, inhibiting, preventing, slowing, or delaying the onset of a neurodegenerative disease in mammals (e.g., humans) via the co-administration of an effective amount of a compound selected from the group consisting of Formula (I), Formula (II), Formula (III) or Formula (IV) or pharmaceutically acceptable salts thereof and an antidiabetic agent. In certain embodiments, the mammal is a type-1 diabetic, a type-2 diabetic, a type-3 diabetic, or has prediabetes.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core portion comprises metformin and a release-preventing agent. The controlled membrane film is provided with at least one passageway. The outer portion comprises a non-biguanide antidiabetic agent. In the oral dosage form, the metformin has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% is released from the oral dosage form at 2 hours, approximately 60-70% is released at 12 hours, and more than 80% is released at 20 hours. Upon a single-dose oral administration, the time that the oral dosage form provides a maximum plasma concentration of the metformin in a subject is from approximately 8 to 20 hours after administration.

The invention relates to the technical field of biological medicine, in particular to a fermented rehmannia root compound with insulin secretion promoting and blood sugar reducing functions and a preparation method and application thereof, the compound is prepared from rehmannia root, folium mori and bitter gourd peptide as raw materials, and lactobacillus plantarum, bifidobacterium bifidum and saccharomyces cerevisiae which are specifically preserved are utilized for synergistic fermentation. The nitrogen-carbon ratio of a fermentation system is accurately controlled within the range of 1: 6-1: 8 through an initiative nitrogen-carbon dynamic monitoring technology, so that newborn small molecular protein CSMI-3 (the molecular weight is 3205.8 Da) is directionally enriched. In-vitro and in-vivo experiments prove that the compound can remarkably promote insulin secretion, reduce fasting blood-glucose and improve insulin resistance, is good in safety and is suitable for developing novel anti-diabetic drugs or functional foods.

The present invention relates to a use of a composition for preventing, alleviating, or treating diabetic kidney disease, the composition comprising zinc salt and cyclo-hispro as active ingredients. More specifically, the present invention provides: a composition for preventing, alleviating, or treating diabetic kidney disease, the composition comprising zinc salt and cyclo-hispro as active ingredients, wherein the composition, when administered alone or in combination with an antihypertensive agent and / or antidiabetic agent, exhibits the effect of preventing, alleviating, or treating diabetic kidney disease through the effect of reducing albuminuria, reducing the albuminuria / creatinine ratio, or increasing the glomerular filtration rate; and a method for preventing, alleviating, or treating diabetic kidney disease using same.

A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.

The invention relates to methods and pharmaceutical compositions effective for treating, inhibiting, preventing, slowing, or delaying the onset of a neurodegenerative disease in mammals (e g., humans) via the co-administration of an effective amount of a compound selected from the group consisting of Formula (I), Formula (II), Formula (III) or Formula (IV) or pharmaceutically acceptable salts thereof and an antidiabetic agent. In certain embodiments, the mammal is a type-1 diabetic, a type-2 diabetic, a type-3 diabetic, or has prediabetes.

A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.

A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.